SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
March 15, 2004 (March 15, 2004)
HEMISPHERX BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-27072 52-0845822
(state or other juris- (Commission (I.R.S. Employer
diction of incorporation) File Number) (Identification No.)
1617 JFK Boulevard, Philadelphia, Pennsylvania 19103
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (215) 988-0080
------------------------------------------------------------
(Former name or former address, if changed since last report)
ITEM 7. Financial Statements And Exhibits.
(c) Exhibits. The following exhibits are filed herewith:
The following exhibit is filed herewith:
Exhibit No. Exhibit Title
99.1 Press Release, dated March 15, 2004 issued by us*
-------------------------------
* This information shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, and shall not be deemed incorporated by
reference in any filing with the Securities and Exchange Commission under the
Securities Exchange Act of 1934 or the Securities Act of 1933, whether made
before or after the date hereof and irrespective of any general incorporation
language in any filings.
ITEM 12. Results of Operations and Financial Condition.
On March 15, 2004, we issued a press release announcing our results for the
fiscal year ended December 31, 2003. A copy of the press release is attached as
Exhibit 99.1 to this report.
The information contained in this report and exhibit attached hereto are being
furnished pursuant to Item 12 of Form 8-K and shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be
deemed incorporated by reference in any filing with the Securities and Exchange
Commission under the Securities Exchange Act of 1934 or the Securities Act of
1933, whether made before or after the date hereof and irrespective of any
general incorporation language in any filings.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
HEMISPHERX BIOPHARMA, INC.
March 15, 2004 By: /s/ William A Carter
--------------------------------
William A. Carter, M.D., President